Ecor1 Capital, LLC has bought stock on 30 days since Jun 2020
10% owner at Atara Biotherapeutics, Inc., and 12 other companies
SEC CIK 0001587114 · Filings on SEC.gov ↗
Ecor1 Capital, LLC's record
3 months after each buy, from the first price a copier could get.
25 buys since 2020 with 3 months of prices.
Companies
- ATRA Atara Biotherapeutics, Inc.10% owner
- TRAX First Tracks Biotherapeutics, Inc.10% owner
- AKTS Aktis Oncology, Inc.Director
- ZYME Zymeworks Inc.Director and 10% owner
- ITOS Iteos Therapeutics, Inc.10% owner
- ANAB AnaptysBio, Inc.Director and 10% owner
- TNGX Tango Therapeutics, Inc.10% owner
- VYGR Voyager Therapeutics, Inc.10% owner
- PRTA Prothena Corporation plc10% owner
- ODT Odonate Therapeutics, Inc.10% owner
- CRVS Corvus Pharmaceuticals, Inc.10% owner
- SURF Surface Oncology, Inc.10% owner
- AKUS Akouos, Inc.10% owner
Every filing
38 filings since Jul 2020, newest first
Atara Biotherapeutics, Inc.
10% owner
First Tracks Biotherapeutics, Inc.
10% owner
Aktis Oncology, Inc.
Director
Zymeworks Inc.
Director and 10% owner
Iteos Therapeutics, Inc.
10% owner
Zymeworks Inc.
Director and 10% owner
Zymeworks Inc.
Director and 10% owner
Zymeworks Inc.
Director and 10% owner
Zymeworks Inc.
Director and 10% owner
Zymeworks Inc.
Director and 10% owner
Zymeworks Inc.
Director and 10% owner
Zymeworks Inc.
Director and 10% owner
Zymeworks Inc.
Director and 10% owner
Zymeworks Inc.
Director and 10% owner
Anaptysbio, Inc
Director and 10% owner
Zymeworks Inc.
Director and 10% owner
Zymeworks Inc.
Director and 10% owner
Zymeworks Inc.
Director and 10% owner
Tango Therapeutics, Inc.
10% owner
Anaptysbio, Inc
10% owner
Zymeworks Inc.
10% owner
Zymeworks Inc.
10% owner
Zymeworks Inc.
10% owner
Zymeworks Inc.
10% owner
Voyager Therapeutics, Inc.
10% owner
Anaptysbio, Inc
10% owner
Prothena Corp Public Ltd Co
10% owner
Prothena Corp Public Ltd Co
10% owner
Odonate Therapeutics, Inc.
10% owner
Corvus Pharmaceuticals, Inc.
10% owner
Anaptysbio, Inc
Director and 10% owner
Anaptysbio, Inc
Director and 10% owner
Prothena Corp Public Ltd Co
10% owner
Anaptysbio, Inc
10% owner
Prothena Corp Public Ltd Co
10% owner
Prothena Corp Public Ltd Co
10% owner
Surface Oncology, Inc.
10% owner
Akouos, Inc.
10% owner
About Ecor1 Capital, LLC
EcoR1 Capital, LLC is a San Francisco-based biotech-focused investment firm founded in 2012 or 2013 by Oleg Nodelman, who serves as its Founder and Portfolio Manager.( The firm specializes in investing across all stages of research and development in the biotechnology sector, particularly in healthcare, life sciences, and oncology, with a patient-driven ethos that emphasizes exceptional management, strong science, and innovative therapeutics.( It manages discretionary assets of approximately $5 billion as reported in early 2024, with a portfolio value around $2-4 billion in recent filings, featuring top holdings such as Zymeworks Inc., AnaptysBio, Inc., and Apellis Pharmaceuticals.(
EcoR1 Capital, LLC operates from 357 Tehama Street, Floor 3, San Francisco, CA, and has established itself as a significant player in biotech investing, holding board positions or significant ownership in companies like Zymeworks (as Director and 10% Owner), AnaptysBio, and Galapagos through its leadership.( The firm recently traded as a Director at Aktis Oncology, Inc. (AKTS), reflecting its active involvement in oncology-related investments.[user query context] With over 30 holdings and a concentrated top-10 portfolio allocation, EcoR1 supports advancements in treatments for cancer, immunology, and autoimmune diseases.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.